SCHEMBL4158701

SCHEMBL4158701

CNc1nc(C)c(-c2ccnc(Nc3cccc(N4CCNCC4)c3)n2)s1

nearest known ligand 0.93

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 18/20 0.93
CDK9 P50750 18/20 0.93
CCNT1 O60563 16/20 0.93
CCNA2 P20248 15/20 0.93
CDK7 P50613 11/20 0.93
CDK1 P06493 11/20 0.93
CCNB1 P14635 10/20 0.93
CCNH P51946 10/20 0.93
CCNA1 P78396 7/20 0.93
WEE1 P30291 2/20 0.79
FLT3 P36888 2/20 0.79
ALK Q9UM73 2/20 0.79
AURKA O14965 2/20 0.79
AURKB Q96GD4 2/20 0.79
CHEK1 O14757 1/20 0.79
DAPK3 O43293 1/20 0.79
JAK2 O60674 1/20 0.79
PRKD3 O94806 1/20 0.79
PAK4 O96013 1/20 0.79
ABL1 P00519 1/20 0.79

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4167320 0.91 CDK2 (0.77) CDK2CDK9CCNT1CCNA2CDK7
SCHEMBL2076213 0.89 CDK2 (1.00) CDK2CDK9CCNT1CCNA2CDK7
SCHEMBL4158723 0.86 CDK9 (1.00) CDK2CDK9CCNT1CCNA2CDK7
SCHEMBL27664773 0.85 CDK2 (0.78) CDK2CDK9CCNT1CCNA2CDK7
SCHEMBL5159347 0.85 CDK2 (0.75) CDK2CDK9CCNT1CCNA2CDK7
SCHEMBL27664777 0.84 CDK2 (0.72) CDK2CDK9CCNT1CCNA2CDK7
SCHEMBL27664830 0.83 CDK2 (0.77) CDK2CDK9CCNT1CCNA2CDK7
SCHEMBL20451995 0.82 CDK4 (0.82) CDK2CDK9CCNT1CCNA2CDK7
SCHEMBL30777167 0.82 CDK4 (0.82) CDK2CDK9CCNT1CCNA2CDK7
SCHEMBL4156961 0.80 CDK2 (0.80) CDK2CDK9CCNT1CCNA2CDK7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090137572-A1 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders CYCLACEL LIMITED (GB) 2009-05-28 US claimed
EP-1756098-A2 2-SUBSTITUTED-4-HETEROARYL-PYRIMIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS Cyclacel Limited (GB) 2007-02-28 EP claimed
WO-2005116025-A2 2-SUBSTITUTED-4-HETEROARYL-PYRIMIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS CYCLACEL LIMITED (GB) 2005-12-08 WO claimed
US-20090137572-A1 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders CYCLACEL LIMITED (GB) 2009-05-28 US disclosed
US-20090137572-A1 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders CYCLACEL LIMITED (GB) 2009-05-28 US disclosed
US-20090137572-A1 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders CYCLACEL LIMITED (GB) 2009-05-28 US disclosed
EP-1756098-A2 2-SUBSTITUTED-4-HETEROARYL-PYRIMIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS Cyclacel Limited (GB) 2007-02-28 EP disclosed
WO-2005116025-A2 2-SUBSTITUTED-4-HETEROARYL-PYRIMIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS CYCLACEL LIMITED (GB) 2005-12-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090137572-A1 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders CDK2, CDK4, CDK20 CDK2 1/4885CDK9 34/4885CCNT1 107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.